The 12 references in paper А. Рычков Ю., Н. Хорькова Ю., Е. Ярославская И. (2014) “РИВАРОКСАБАН ПРИ ТРОМБОЗЕ ЛЕВОГО ПРЕДСЕРДИЯ У ПАЦИЕНТА С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ ПРИ ПРОВЕДЕНИИ КАТЕТЕРНОЙ АБЛЯЦИИ” / spz:neicon:aterotromboz:y:2014:i:2:p:82-85

1
Clinical arrhythmology and electrophysiology: a companion to Braunwald’s heart disease. Ed by Issa ZF, Miller JM, Zipes DP. Elsevier Inc., 2012: 726.
(check this in PDF content)
2
Luna AB. Clinical arrhythmology. Wiley-Blackwell. 2011: 428.
(check this in PDF content)
3
Диагностика и лечение фибрилляции предсердий, рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал, 2014, 4 (102), 3.
(check this in PDF content)
4
Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med.,2011, 365: 883-891.
(check this in PDF content)
5
Lakkireddy D, Reddy YM, Di Biase L et al. Feasibility & Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation: Results from a Multicenter Prospective Registry. J Am Coll Cardiol., 2014, 18, 63(10): 982-988.
(check this in PDF content)
6
Hammerstingl C, Potzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thrombosis and Haemostasis,2013, 109: 583–584.
(check this in PDF content)
7
Takasugi J, Yamagami H, Okata T et al. Dissolution of the left atrial appendage thrombus with rivaroxaban therapy. Cerebrovascular Diseases, 2013, 36: 322-323.
(check this in PDF content)
8
Gerotziafas G, Elalamy I, Depasse F et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost., 2007, 5: 886–888.
(check this in PDF content)
9
Varin R, Mirshahi S, Mirshahi P et al. Whole blood clots are more resistantto lysis than plasma clots — greater efficacy of rivaroxaban. Thromb Res.,2013, 131:
(check this in PDF content)
10
109. 10. January CT, Wann LS, Alpert JS at al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol., 2014, 28. pii: S0735-1097(14)01740-9.
(check this in PDF content)
11
Dillier R, Ammar S, Hessling G et al. Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circ Arrhythm Electrophysiol., 2014, 7(4): 576-582.
(check this in PDF content)
12
Naccarelli GV, Cappato R, Hohnloser SH et al. Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation
(check this in PDF content)